Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 11, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than financial performance data.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On April 9, 2007, there was an increase in the notional allocation of Ordinary Share ADRs at a price of $56.12 per share for Mrs. C Bruck Slaoui.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- The transaction involves an increase in notional allocation of GSK Ordinary Share ADRs for Mrs. C Bruck Slaoui.
- The transaction price was $56.12 per share on April 9, 2007.
- The filing relates to the US Retirement Savings Plan and does not contain consolidated financial results.